| Literature DB >> 24951635 |
Ianna Lacerda Sampaio Braga1, Patricia Natalia Silva1, Tatiane Katsue Furuya1, Leonardo Caires Santos1, Belisa Caldana Pires1, Diego Robles Mazzotti1, Paulo Henrique Bertolucci2, Maysa Seabra Cendoroglo3, Marília Cardoso Smith4.
Abstract
The loss of cholinergic transmission is considered to be an important cause of Alzheimer's disease (AD). Treatment with acetyl cholinesterase inhibitors (ChEIs) shows benefits; however, great heterogeneity has been observed in patient responses. We evaluated apolipoprotein E (APOE) and α7 nicotinic receptor (CHRNA7) single-nucleotide polymorphisms (SNPs) and associated these SNPs with pharmacological responses to ChEIs in a Brazilian population with AD. We studied 177 outpatients using ChEIs, and they were classified as responders and nonresponders according to variation in Mini-Mental State Examination (MMSE) status. The analysis of APOE genotypes showed that patients with the ε4 allele had a worse response than those without the ε4 allele. We observed an association between the CHRNA7 T allele and a better response to treatment with ChEIs in patients with mild AD (MMSE ≥ 20). The SNP rs6494223 of CHRNA7 as well as APOEε4 could be useful for understanding the response to ChEI treatment in patients with AD.Entities:
Keywords: APOE; Alzheimer’s disease; CHRNA7; cholinesterase inhibitor; pharmacogenomics
Mesh：
Substances：
Year: 2014 PMID： 24951635 DOI： 10.1177/1533317514539540
Source DB: PubMed Journal: Am J Alzheimers Dis Other Demen ISSN： 1533-3175 Impact factor: 2.035